Fate Therapeutics announces completion of public offering of common stock
Fate Therapeutics announced the closing of an underwritten public offering of 10,648,149 shares of its common stock, which included 1,388,889 shares that were issued pursuant to the full exercise of the underwriters’ option. Gross proceeds were $143.8 million. September 25, 2018